Marijuana for Symptoms of PTSD in U.S. Veterans
https://maps.org/research/mmj/marijuana-us/
Placebo-Controlled, Triple-Blind, Randomized Crossover Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans with Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)
Site Principal Investigator: Sue Sisley, M.D.
Coordinating Principal Investigator: Marcel Bonn-Miller, Ph.D.
Co-Investigator: Paula Riggs, M.D.
This study has completed enrollment.
This study will explore whether smoked marijuana can help reduce PTSD symptoms in 76 U.S. veterans with chronic, treatment-resistant posttraumatic stress disorder (PTSD). Participants must be U.S. veterans, men or women, aged 18 or older with a diagnosis of PTSD that has not improved after trying either medication or psychotherapy.
$2,156,000 estimated study budget • $2,156,000 grant awarded by the State of Colorado
- Study Protocol (Amendment 8, Version 2: December 4, 2017)
- PRESS RELEASE: Statement on the Adequacy of Marijuana Provided by NIDA for Phase 2 Clinical Trials for PTSD in Veterans (March 17, 2017)
- PRESS RELEASE: First Clinical Trial of Marijuana for PTSD in Veterans Nearly Completes Enrollment (August 9, 2018)
View the complete timeline of this study.
View the timeline of MAPS’ efforts to conduct marijuana research